A miniaturized, DNA-FET biosensor-based microfluidic system for quantification of two breast cancer biomarkers

Breast cancer is among the frequently diagnosed cancers worldwide and is associated with a high mortality rate, especially when diagnosed late. Minimally invasive screening approaches based on an assessment of extracellular vesicle (EV)-encapsulating microRNA biomarkers have enabled earlier diagnosi...

Full description

Saved in:
Bibliographic Details
Published in:Microfluidics and nanofluidics 2021-04, Vol.25 (4), Article 33
Main Authors: Huang, Chi-Chien, Kuo, Yu-Hsuan, Chen, Yi-Sin, Huang, Po-Chiun, Lee, Gwo-Bin
Format: Article
Language:English
Subjects:
Analytical Chemistry
Biomarkers
Biomedical Engineering and Bioengineering
Biosensors
Breast cancer
Cancer
CMOS
Deoxyribonucleic acid
Diagnosis
DNA
Electric vehicles
Engineering
Engineering Fluid Dynamics
Extracellular
Extracellular vesicles
Field effect transistors
Hybridization
Metals
Microfluidics
MicroRNAs
miRNA
Nanotechnology and Microengineering
Research Paper
Ribonucleic acid
RNA
Sensors
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Breast cancer is among the frequently diagnosed cancers worldwide and is associated with a high mortality rate, especially when diagnosed late. Minimally invasive screening approaches based on an assessment of extracellular vesicle (EV)-encapsulating microRNA biomarkers have enabled earlier diagnosis and improved survival rates. Since field-effective transistors (FET) featuring complementary metal oxide semiconductor technology have been previously converted into highly sensitive biosensors, an integrated microfluidic system (IMS) was developed herein for quantifying concentrations of breast cancer biomarkers including microRNA-195 and microRNA-126. Following a (1) 4-h process in which 84% of the EVs were captured, (2) 20-min hybridization step in which 85 and 94% of the microRNA-195 and microRNA-126 were isolated, respectively, and (3) the DNA-FET biosensors could detect down to 84 and 75 aM concentrations of microRNA-195 and microRNA-126, respectively. The IMS automated the entire biomarker quantification process within 5 h, highlighting its potential as a sensitive platform for early-stage breast cancer diagnosis.
ISSN:1613-4982
1613-4990
DOI:10.1007/s10404-021-02437-8